ATTRACTION-5

NCT03006705 📎

Regimen

Experimental
nivolumab + adjuvant S-1 or CapOx chemotherapy
Control
placebo + adjuvant S-1 or CapOx chemotherapy

Population

Asian patients with stage III gastric/GEJ cancer after D2+ gastrectomy

Key finding

3y RFS 68.4% vs 65.3% (HR 0.90, 95.72% CI 0.69-1.18, p=0.44); negative for adj IO in Asian stage III G/GEJ after D2

Source: PMID 38906161

Timeline

    Guideline citations

    • NCCN GASTRIC (p.126)
    • CSCO GASTRIC 2025 (p.63)⚠️ OCR source